Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting

Bibliography

• Pardeshi CV, Rajput PV, Belgamwar VS, Tekade AR. Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for Valsartan. J Microencapsul 2011;29:103-14
   PubMed Web of Science ®Google Scholar
• Jadhav KR, Gambhire MN, Shaikh IM, et al. Nasal drug delivery system- factors affecting and applications. Curr Drug Ther 2007;2:27-38
   Google Scholar
• Davis SS. Biomedical applications of nanotechnology – Implications for drug targeting and gene therapy. Trends Biotechnol 1997;15:217-24
   PubMed Web of Science ®Google Scholar
• Colombo G, Lorenzini L, Zironi E, et al. Brain distribution of ribavirin after intranasal administration. Antiviral Res 2011;92:408-14
   PubMed Web of Science ®Google Scholar
• Chen J, Wang X, Wang J, et al. Evaluation of brain-targeting for the nasal delivery of ergoloid mesylate by the microdialysis method in rats. Eur J Pharm Biopharm 2008;68:694-700
   PubMed Web of Science ®Google Scholar
• Ali J, Ali M, Baboota S. Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Res 2010;10:1644-53
   Google Scholar
• Alam MI, Beg S, Samad A, et al. Strategy for effective brain drug delivery. Eur J Pharm Sci 2010;40:385-403
   PubMed Web of Science ®Google Scholar
• Haque S, Md S, Fazil M, et al. Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation. Carbohydr Polym 2012;89:72-9
   PubMed Web of Science ®Google Scholar
• Wang X, Chi N, Tang X. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 2008;70:735-40
   PubMed Web of Science ®Google Scholar
• Shahiwala A, Dash D. Preparation and Evaluation of Microemulsion Based Formulations for Rapid-Onset Intranasal Delivery of Zonisamide. Adv Sci Lett 2010;3:442-6
   Web of Science ®Google Scholar
• Kumar M, Pathak K, Misra A. formulation and characterization of nanoemulsion-based drug delivery system of risperidone. Drug Dev Ind Pharm 2009;35:387-95
   PubMed Web of Science ®Google Scholar
• Kumar M, Misra A, Babbar AK, et al. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008;358:285-91
   PubMed Web of Science ®Google Scholar
• Kumar M, Misra A, Mishra AK, et al. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J Drug Target 2008;10:806-14
   Google Scholar
• Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater 2011;7:4169-76
   PubMed Web of Science ®Google Scholar
• Khan S, Patil K, Bobade N, et al. Formulation of intranasal mucoadhesive temperature- mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target 2010;3:223-34
   Google Scholar
• Jain R, Nabar S, Dandekar P, Patravale V. Micellar nanocarriers: potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharm Res 2010;4:655-64
   Google Scholar
• Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009;379:146-57
   PubMed Web of Science ®Google Scholar
• Illum L. Nasal drug delivery—possibilities, problems and solutions. J Control Release 2003;87:187-98
   PubMed Web of Science ®Google Scholar
• Illum L. Nasal clearance in health and disease. J Aerosol Med 2006;1:92-9
   Google Scholar
• Oberdorster G, Sharp Z, Atudorei V, et al. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 2004;16:437-45
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood–brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm 2005;298:274-92
   PubMed Web of Science ®Google Scholar
• Talegaonkar S, Mishra PR. Intranasal delivery: an approach to bypass the blood brain barrier. Indian J Pharmacol 2004;4:140-7
   Google Scholar
• Bhise SB, Yadav AV, Avachat AM, Malayandi R. Bioavailability of intranasal drug delivery system. Asian J Pharm 2008;4:201-15
   Google Scholar
• Dhuria SV, Hanson LR, Frey WH II. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99:1654-73
   PubMed Web of Science ®Google Scholar
• Thorne RG, Pronk GJ, Padmanabhan V, Frey WH. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127:481-96
   PubMed Web of Science ®Google Scholar
• Johnston M, Zakharov A, Papaiconomou C, et al. Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res 2004;1:2
   PubMedGoogle Scholar
• Walter BA, Valera VA, Takahashi S, et al. Evidence of the antibody production in rat cervical lymph nodes after antigen administration into the cerebrospinal fluid. Arch Histol Cytol 2006;69:37-47
   PubMed Web of Science ®Google Scholar
• Born J, Lange T, Kern W, et al. Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002;5:514-16
   PubMed Web of Science ®Google Scholar
• Sakane T, Akizuki M, Yamashita S, et al. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the dissociation of the drug. J Pharm Pharmacol 1994;46:378-9
   PubMed Web of Science ®Google Scholar
• Banks WA, During MJ, Niehoff ML. Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol Exp Ther 2004;309:469-75
   PubMed Web of Science ®Google Scholar
• Ross TM, Martinez PM, Renner JC, et al. Intranasal administration of interferon beta bypasses the blood brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 2004;151:66-77
   PubMed Web of Science ®Google Scholar
• Khanvilkar K, Donovan MD, Flanagan DR. Drug transfer through mucus. Adv Drug Deliv Res 2001;48:173-93
   PubMed Web of Science ®Google Scholar
• Sakane T, Akizuki M, Yamashita S, et al. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem Pharm Bull 1991;39:2456-8
   PubMed Web of Science ®Google Scholar
• Singh RMP, Kumar A, Pathak K. Mucoadhesive in situ nasal gelling drug delivery systems for modulated drug delivery. Expert Opin Drug Deliv 2013;10:115-30
   PubMed Web of Science ®Google Scholar
• Hounam RF, Black A, Walsh M. The deposition of aerosol particles in the nasopharyngeal region of the human respiratory tract. Inhaled Part 1970;1:71-80
   PubMedGoogle Scholar
• Bates DV, Fish BR, Hatch TF, et al. Deposition and retention models for internal dosimetry of human respiratory tract. Task group on lung dynamics. Health Phys 1966;12:173-207
   PubMed Web of Science ®Google Scholar
• Proctor DF, Anderson I, Lundqvist G. Clearance of inhaled particle from human nose. Arch Intern Med 1973;131:132-9
   PubMed Web of Science ®Google Scholar
• Kublik H, Vidgren MT. Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 1998;29:157-77
   PubMed Web of Science ®Google Scholar
• Mygind N, Vesteraugh S. Aerosol distribution in the nose. Rhinology 1978;16:79-88
   PubMedGoogle Scholar
• Mourya VK, Inamdar NN. Chitosan-modifications and applications: opportunities galore. React Funct Polym 2008;68:1013-51
   Web of Science ®Google Scholar
• Mistry A. The development and application of biological models for evaluation of direct nose-to-brain drug delivery systems. 2008.Thesis, University of Nottingham, UK. Available from: http://etheses.nottingham.ac.uk/654/1/Thesis_-_Alpesh_Mistry.pdf
   Google Scholar
• Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005;113:823-39
   PubMed Web of Science ®Google Scholar
• Casettari L, Vllasaliu D, Castagnino E, et al. PEGylated chitosan derivatives: synthesis, characterizations and pharmaceutical applications. Prog Polym Sci 2010;5:659-85
   Google Scholar
• Lai SK, O'Hanlon DE, Harrold S, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci USA 2007;104:1482-7
   PubMed Web of Science ®Google Scholar
• Wang YY, Lai SK, Suk JS, et al. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “Slip”. Through the human mucus barrier. Angew Chem Int Ed Engl 2008b;47:9726-9
   PubMed Web of Science ®Google Scholar
• Goppert TM, Muller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J Drug Target 2005;13:179-87
   PubMed Web of Science ®Google Scholar
• Gao XL, Tao WX, Lu W, et al. Lectin-conjugated PEG–PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials 2006;27:3482-90
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Isayama Y. Evidence for sialyl glycoconjugates as receptors for Bordetella bronchiseptica on swine nasal mucosa. Infect Immun 1987;55:1607-9
   PubMed Web of Science ®Google Scholar
• Gao X, Wu B, Zhang Q, et al. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J Control Release 2007;121:156-67
   PubMed Web of Science ®Google Scholar
• Liu Q, Shao X, Chen J, et al. In vivo toxicity and immunogenicity of wheat germ agglutinin conjugated poly (ethylene glycol)-poly(lactic acid) nanoparticles for intranasal delivery to the brain. Toxicol Appl Pharmacol 2011;251:79-84
   PubMed Web of Science ®Google Scholar
• Patel S, Chavhan S, Soni H, et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target 2011;19:468-74
   PubMed Web of Science ®Google Scholar
• Pardeshi CV, Rajput PV, Belgamwar VS, et al. Novel surface-modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach. Drug Deliv 2013;20:47-56
   PubMed Web of Science ®Google Scholar
• Xia H, Gao X, Gu G, et al. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 2011;32:9888-98
   PubMed Web of Science ®Google Scholar
• Wearly LL. Recent progress in protein and peptide delivery by noninvasive routes. Crit Rev Ther Drug Carrier Syst 1991;8:331-94
   PubMed Web of Science ®Google Scholar
• Chen XQ, Fawcett JR, Rahman YE, et al. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimers Dis 1998;1:35-44
   PubMedGoogle Scholar
• Liu X, Fawcett JR, Thorne RG, Frey II WH. Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci Lett 2001;308:91-4
   PubMed Web of Science ®Google Scholar
• Gozes I, Bardea A, Reshef A, et al. Neuroprotective strategy for Alzheimers disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci USA 1996;93:427-32
   PubMed Web of Science ®Google Scholar
• Hanson LR, Fine JM, Hoekman JD, et al. Intranasal delivery of growth differentiation factor 5 to the central nervous system. Drug Deliv 2012;19:149-54
   PubMed Web of Science ®Google Scholar
• Pietrowsky R, Struben C, Molle M, et al. Brain potential changes after intranasal administration Vs. intravenous administration of vasopressin: evidence for a direct nose- brain pathway for peptide effects in humans. Biol Psychiatry 1996;39:332-40
   PubMed Web of Science ®Google Scholar
• Pietrowsky R, Thieman A, Kern W, et al. A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin. Psychoneuroendocrinology 1996;21:559-72
   PubMed Web of Science ®Google Scholar
• Fehm HL, Smolnik R, Kern W, et al. The melanocortin melanocyte-stimulating hormone/adrenocotropin(4-10) decreases body fat in humans. J Clin Endocrinol Metab 2001;3:1144-8
   Google Scholar
• Kern W, Born J, Schreiber H, Fehm HL. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes 1999;48:557-63
   PubMed Web of Science ®Google Scholar
• Hinchcliff M, Illum L. Intranasal insulin delivery and therapy. Adv Drug Deliv Rev 1999;35:199-234
   PubMed Web of Science ®Google Scholar
• Gozes I, Giladi E, Pinhasov A, et al. Activity-dependent Neurotropic factor: intranasal administration of femtomolar-acting peptides improves performance in a water maze. J Pharmacol Exp Ther 2000;293:1091-8
   PubMed Web of Science ®Google Scholar
• Wolf DA, Hanson LR, Aronovich EL, et al. Lysosomal enzyme can bypass the blood–brain barrier and reach the CNS following intranasal administration. Mol Genet Metab 2012;106:131-4
   PubMed Web of Science ®Google Scholar
• Hallschmid M, Benedict C, Schultes B, et al. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept 2008;149:79-83
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH II. Novel Vasoconstrictor Formulation to Enhance Intranasal Targeting of Neuropeptide Therapeutics to the Central Nervous System. J Pharmacol Exp Ther 2009;328:312-20
   PubMed Web of Science ®Google Scholar
• Benedict C, Frey II WH, Schioth HB, et al. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol 2011;46:112-15
   PubMed Web of Science ®Google Scholar
• Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004;29:1326-34
   PubMed Web of Science ®Google Scholar
• Schioth HB, Craft S, Brooks SJ, et al. Brain Insulin Signaling and Alzheimer's Disease: current Evidence and Future Directions. Mol Neurobiol 2012;46:4-10
   PubMed Web of Science ®Google Scholar
• Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment a pilot clinical trial. Arch Neurol 2012;69:29-38
   PubMed Web of Science ®Google Scholar
• Vajdy M, O'Hagan DT. Microparticles for intranasal immunization. Adv Drug Deliv Rev 2001;51:127-41
   PubMed Web of Science ®Google Scholar
• Oh YK, Kim JP, Hwang TS, et al. Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. Vaccine 2001;31:4519-25
   Google Scholar
• Dahlin M, Jansson B, Bjork E. Levels of dopamine in blood and brain following nasal administration to rats. Eur J Pharm Sci 2001;14:75-80
   PubMed Web of Science ®Google Scholar
• Li L, Nandi I, Kim KH. Development of ethyl laurate-based microemulsion for rapid-onset intranasal administration of diazepam. Int J Pharm 2002;237:77-85
   PubMed Web of Science ®Google Scholar
• Danielyan L, Schafer R, von Ameln-Mayerhofer A, et al. Intranasal delivery of cells to the brain. Eur J Cell Biol 2009;88:315-24
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhu J, Xu G, Liu X. Intranasal delivery of stem cells to the brain. Expert Opin Drug Deliv 2011;8:623-32
   PubMed Web of Science ®Google Scholar
• Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012;64:614-28
   PubMed Web of Science ®Google Scholar
• Shihabuddin LS, Aubert I. Stem cell transplantation for neurometabolic and neurodegenerative diseases. Neuropharmacology 2010;58:845-54
   PubMed Web of Science ®Google Scholar
• Huang B, Tabata Y, Gao JQ. Mesenchymal stem cells as therapeutic agents and potential targeted gene delivery vehicle for brain diseases. J Control Release 2012;162:464-73
   PubMed Web of Science ®Google Scholar
• Danielyan L, von Ameln-Mayerhofer A, Bernhard F, et al. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res 2011;14:3-16
   PubMed Web of Science ®Google Scholar
• Frey WH II. Method for administering neurological agents to the brain. US6180603B1; 2001
   Google Scholar
• Frey WH II. Method for administering insulin to the brain. US6313093B1; 2001
   Google Scholar
• Frey WH II, Danielyan L, Christoph H. Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system. US8283160B2; 2012
   Google Scholar
• Frey WH II. Administration of neurotrophic agents to the central nervous system. EP 1137401 B1; 2005
   Google Scholar
• Frey WH II. Method for administering neurological agents to the brain. US5624898; 1997
   Google Scholar
• Frey WH II, Thorne RG. Method for administering agents to the central nervous system. US0072793A1; 2003
   Google Scholar
• Frey WH II. Method for administering brain-derived neurotropic factor to the brain. US0215398A1; 2003
   Google Scholar
• Meyerson LR, Went GT, Fultz TJ. Methods and compositions for the treatment of CNS-related conditions. US0245617A1; 2005
   Google Scholar
• Meyerson LR, Went GT, Fultz TJ, Burkoth TS. Methods and composition for treating migraine pain. US0240043A1; 2006
   Google Scholar
• Levin BH. Directed intranasal administration of pharmaceutical agents. US0281751A1; 2005
   Google Scholar
• Went GT, Fultz TJ. Methods and compositions for the treatment of CNS-related conditions. US0252788A1; 2006
   Google Scholar
• Frenkel D, Maron R, Burt D, Weiner HL. Compositions and methods for treating neurological disorders. US0229233A1; 2006
   Google Scholar
• Choi YM, Kim KH. Transnasal microemulsions containing diazepam. US0002987A1; 2005
   Google Scholar
• Choi YM, Kim KH. Transnasal microemulsions containing diazepam. WO04110403A1; 2004
   Google Scholar
• Misra A, Vyas TK. Drugs loaded nasoadhesive microemulsions for brain targeted brisk delivery in acute epilepsy. 1061/MUM/2004; 2005
   Google Scholar
• Misra A, Vyas TK. Sedatives loaded intranasal nasoadhesive microemulsions for brain targeted delivery in insomnia. 1124/MUM/2004; 2005
   Google Scholar
• Misra A, Vyas TK. Drugs loaded intranasal nasoadhesive microemulsions for brain targeted delivery in migraine. 1125/MUM/2004; 2005
   Google Scholar
• Wermeling DP. System and method for intranasal administration of lorazepam. US6610271B2; 2003
   Google Scholar
• Wermeling DP. System and method for intranasal administration of lorazepam. US0055571A1; 2001
   Google Scholar
• Castile JD, Cheng YH, Jenkins PG, et al. Intranasal compositions. US0140981A1; 2007
   Google Scholar
• Pathan SA, Iqbal Z, Zaidi SMA, et al. CNS Drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul 2009;3:71-89
   PubMedGoogle Scholar